Hitachi Chemical Co. America, Ltd. (San Jose, California), a subsidiary of Hitachi Chemical (Tokyo) has completed its purchase of the 80.1% remaining membership interest in PCT Cell Therapy Services (PCT, New Jersey) from Caladrius Biosciences.
Following the acquisition, PCT has become an independent business unit dedicated to cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical.
Hitachi Chemical will leverage PCT’s extensive experience in cell therapy development and manufacturing technology, wide-ranging manufacturing locations, sales network and other resources to expand and strengthen services in the United States and add services in Japan, Europe, and other regions. In addition, PCT will be able to expand manufacturing capacity, capabilities, and service offerings.
“The acquisition of PCT marks an important milestone in the expansion of Hitachi Chemical’s regenerative medicine-related businesses,” says Hisashi Maruyama, CEO, Hitachi Chemical.
By Kartik Kohli
Source: Chemical Week
Neste Corporation’s Board of Directors has appointed Heikki Malinen, M.Sc. (Econ.), MBA (Harvard) as the President and CEO of Neste as of 2 November 2024, at the latest. Malinen joins Neste from Outokumpu Corporation where he has held the position of President and CEO since 2020.
Petrochemicals company Sasol has announced that CFO and executive director Hanré Rossouw will step down from his position, effective October 31. Sasol has started the process to appoint a successor. Rossouw will still oversee the publication of Sasol’s reports for the financial year ending June 30, to allow for a structured handover period.
Chemours announced its CFO Jonathan Lock has resigned from all positions within the company, according to an SEC 8-K filing on April 23. The resignation comes in the aftermath of the company announcing that Lock, former CEO Mark Newman, and principal accounting officer Camela Wisel, had been placed on administrative leave.